| Autor: |
Azza G Antar Farag, Mostafa A Hammam, Dalia R Al-Sharaky, Reem A Hassan, Eman N ElShafey, Nehal A Ali |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Journal of the Egyptian Women’s Dermatologic Society, Vol 16, Iss 2, Pp 97-104 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2090-2565 |
| DOI: |
10.4103/JEWD.JEWD_4_19 |
| Popis: |
Background Chemokine ligand 22 (CCL22) is a heparin-binding immunomodulator protein that plays an important role in a variety of autoimmune diseases. Narrow-band ultraviolet B (NB-UVB) therapy was considered a cornerstone in the treatment of vitiligo. However, the mechanism of action of NB-UVB in vitiligo has not been completely elucidated. Objective To study the hypothesized role of CCL22 in vitiligo etiopathogenesis and to detect its possible role in NB-UVB-induced pigmentation in vitiligo through its lesional immunohistochemical evaluation in patients with vitiligo before and after ultraviolet B phototherapy. Patients and methods A total of 33 patients with vitiligo versus 20 patients of age-matched, sex-matched, and skin phototype-matched healthy controls were enrolled in this case–control study. Patients were treated with NB-UVB three sessions weekly for 12 weeks. Vitiligo Area Scoring Index score was evaluated before and after NB-UVB sessions. For patients with vitiligo, baseline CCL22 immunohistochemical staining was estimated, and compared with that of controls and with its posttreatment data in those patients. Results Baseline CCL22 immunohistochemical studied parameters were insignificantly lower in patients with vitiligo than controls except its cellular localization (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
